# NCT05320692 (NCT05320692)

> A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05320692
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Conditions: Hepatocellular Carcinoma
- Interventions: TACE+Camrelizumab+Apatinib mesylate; TACE
- Enrollment: 423
- Primary outcome: PFS assessed by BIRC

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05320692